The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Survival outcomes associated with liver-directed therapies in patients with metastatic uveal melanoma.
 
Michael M Caplan
No Relationships to Disclose
 
Lanyi Nora Chen
No Relationships to Disclose
 
Venkatesh Krishnasamy
Consulting or Advisory Role - AngioDynamics; Boston Scientific; Cook Medical; Instylla; Philips, Inc.; Teleflex Medical; TriSalus Life Sciences
Research Funding - Argon Medical Devices; Instylla
 
David Sperling
No Relationships to Disclose
 
Joshua Weintraub
No Relationships to Disclose
 
David DeStephano
No Relationships to Disclose
 
Samuel M Pan
No Relationships to Disclose
 
Diana McDonnell
No Relationships to Disclose
 
Brian P Marr
Consulting or Advisory Role - Aura Biosciences; Castle Biosciences
 
Richard D. Carvajal
Consulting or Advisory Role - Alkermes; Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Aura Biosciences; Bristol-Myers Squibb/Celgene; Bristol-Myers Squibb/Medarex (Inst); Castle Biosciences; Chimeron Bio; Corvus Pharmaceuticals (Inst); Delcath Systems; Eisai; Genzyme; Hengrui Pharmaceutical; IDEAYA Biosciences; IDEAYA Biosciences (Inst); Immunocore; InxMed; Iovance Biotherapeutics; Merck; Mirati Therapeutics (Inst); Novartis; Novartis (Inst); Oncosec; Pfizer (Inst); Pierre Fabre; Plexxikon (Inst); PureTech; Regeneron; Rgenix; Roche/Genentech (Inst); Roche/Genentech (Inst); Sorrento Therapeutics; TriSalus Life Sciences
Speakers' Bureau - Bristol-Myers Squibb/Medarex
Research Funding - Amgen (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Incyte (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst); Regeneron (Inst); Roche/Genentech (Inst)
 
Shaheer Khan
Consulting or Advisory Role - Castle Biosciences
Research Funding - Incyte (Inst)